Comparison of an in-house and a commercial RDI-based ELISPOT-IFN-γ assay for the diagnosis of Mycobacterium tuberculosis infection

Clinical Medicine and Research

Volumn 4, Issue 4, 2006, Pages 266-272

  Mantegani, Paolo ^a   Piana, Federica ^a   Codecasa, Luigi ^b   Galli, Laura ^a   Scarpellini, Paolo ^a   Lazzarin, Adriano ^a,c   Cirillo, Daniela ^a   Fortis, Claudio ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b OSPEDALE NIGUARDA CA GRANDA   (Italy)

^c VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Bacillus Calmette Gu rin; CFP 10; ELISPOT; ESAT 6; Household contacts; IFN g; PPD; Tuberculin skin test; Tuberculosis

Indexed keywords

BACTERIAL PROTEIN; BCG VACCINE; GAMMA INTERFERON;

ADULT; AGED; ARTICLE; CHILD; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; GEOGRAPHIC DISTRIBUTION; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MYCOBACTERIUM TUBERCULOSIS; TUBERCULIN TEST; TUBERCULOSIS;

EID: 33846496757     PISSN: 15394182     EISSN: None     Source Type: Journal    
DOI: 10.3121/cmr.4.4.266     Document Type: Article

References (23)

1. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 1999;282:677-686.
2. American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000;161:S221-S247.
3. Pai M, Riley LW, Colford JM Jr. Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect Dis 2004;4:761-776.
4. Berthet FX, Rasmussen PB, Rosenkrands I, Andersen P, Gicquel B. A Mycobacterium tuberculosis operon encoding ESAT-6 and a novel low-molecular-mass culture filtrate protein (CFP-10). Microbiology 1998;144:3195-3203.
5. Arend SM, Geluk A, van Meijgaarden KE, van Dissel JT, Theisen M, Andersen P, Ottenhoff TH. Antigenic equivalence of human T-cell responses to Mycobacterium tuberculosis-specific RD1-encoded protein antigens ESAT-6 and culture filtrate protein 10 and to mixtures of synthetic peptides. Infect Immun 2000;68:3314-3321.
6. Scarpellini P, Tasca S, Galli L, Beretta A, Lazzarin A, Fortis C. Selected pool of peptides from ESAT-6 and CFP-10 proteins for detection of Mycobacterium tuberculosis infection. J Clin Microbiol 2004;42:3469-3474.
7. Lalvani A. Spotting latent infection: the path to better tuberculosis control. Thorax 2003;58:916-918.
8. Codecasa LR, Besozzi G. Acceptance of isoniazid preventive treatment by close contacts of tuberculosis cases: a 692-subject Italian study. Int J Tuberc Lung Dis 1998;2:208-212.
9. American Thoracic Society. Diagnostic standards and classification of tuberculosis in adults and children. Am J Respir Crit Care Med 2000;161:1376-1395.
10. nd ed. New York, NY: John Wiley & Sons Inc.; 1981.
11. Mustafa AS, Oftung F, Amoudy HA, Madi NM, Abal AT, Shaban F, Rosen Krands I, Andersen P. Multiple epitopes from the Mycobacterium tuberculosis ESAT-6 antigen are recognized by antigen-specific human T cell lines. Clin Infect Dis 2000;30:S201-S205.
12. Ravn P, Demissie A, Eguale T, Wondwosson H, Lein D, Amoudy HA, Mustafa AS, Jensen AK, Holm A, Rosenkrands I, Oftung F, Olobo J, von Reyn F, Andersen P. Human T cell responses to the ESAT-6 antigen from Mycobacterium tuberculosis. J Infect Dis 1999;179:637-645.
13. Lalvani A, Nagvenkar P, Udwadia Z, Pathan AA, Wilkinson KA, Shastri JS, Ewer K, Hill AV, Mehta A, Rodrigues C. Enumeration of T cells specific for RD1-encoded antigens suggests a high prevalence of latent Mycobacterium tuberculosis infection in healthy urban Indians. J Infect Dis 2001;183:469-477.
14. Rieder HL. Epidemiologic basis of tuberculosis control. Paris, France: International Union Against Tuberculosis; 1999.
15. Cohen T, Murray M. Incident tuberculosis among recent US immigrants and exogenous reinfection. Emerg Infect Dis 2005;11:725-728.
16. DeAngelis CD, Flanagin A. Tuberculosis-a global problem requiring a global solution. JAMA 2005;293:2793-2794.
17. Askenase PW, Atwood JE. Basophils in tuberculin and "Jones- Mote" delayed reactions of humans. J Clin Invest 1976;58:1145-1154.
18. Fine PE, Ponnighaus JM, Maine N. The distribution and implications of BCG scars in northern Malawi. Bull World Health Organ 1989;67:35-42.
19. Jasmer RM, Nahid P, Hopewell PC. Clinical practice. Latent tuberculosis infection. N Engl J Med 2002;347:1860-1866.
20. Shams H, Weis SE, Klucar P, Lalvani A, Moonan PK, Pogoda JM, Ewer K, Barnes PE Enzyme-linked immunospot and tuberculin skin testing to detect latent tuberculosis infection. Am J Respir Crit Care Med 2005;172:1161-1168.
21. Codecasa L, Mantegani P, Galli L, Lazzarin A, Scarpellini P, Fortis C. An in-house RD1-based enzyme-linked immunospot-gamma interferon assay instead of the tuberculin skin test for diagnosis of latent Mycobacterium tuberculosis infection. J Clin Microbiol 2006;44:1944-1950.
22. Fietta A, Meloni F, Cascina A, Morosini M, Marena C, Troupioti P, Mangiarotti P, Casali L. Comparison of a whole-blood interferon-gamma assay and tuberculin skin testing in patients with active tuberculosis and individuals at high or low risk of Mycobacterium tuberculosis infection. Am J Infect Control 2003;31:347-353.
23. Hill PC, Brookes RH, Fox A, Fielding K, Jeffries DJ, Jackson-Sillah D, Lugos MD, Owiafe PK, Donkor SA, Hammond AS, Otu JK, Corrah T, Adegbola RA, McAdam KP. Large-scale evaluation of enzyme-linked immunospot assay and skin test for diagnosis of Mycobacterium tuberculosis infection against a gradient of exposure in The Gambia. Clin Infect Dis 2004;38:966-973.